We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
Bath & Body Works
BBWI
$3.37B
| $141K | ﹤0.01% |
3,620
+2,655
| +275% | +$122K |
|
1527
Mineralys Therapeutics
MLYS
$2.44B
| $140K | ﹤0.01% |
12,000
+6,000
| +100% | +$75.6K |
|
1528
Charter Communications
CHTR
$16.1B
| $139K | ﹤0.01% |
466
-85
| -15% | -$23.2K |
|
1529
DigitalBridge
DBRG
$2.98B
| $139K | ﹤0.01% |
10,166
+9,193
| +945% | +$139K |
|
1530
ACM Research
ACMR
$4.46B
| $138K | ﹤0.01% |
6,002
+4,918
| +454% | +$124K |
|
1531
Nicolet Bankshares
NIC
$3.49B
| $137K | ﹤0.01% |
1,653
| – | – |
|
1532
DuPont de Nemours
DD
$17.2B
| $137K | ﹤0.01% |
1,358
-621
| -31% | -$60.8K |
|
1533
10x Genomics
TXG
$9.46B
| $136K | ﹤0.01% |
+7,000
| New | +$183K |
|
1534
TXO Partners LP
TXO
$820M
| $136K | ﹤0.01% |
6,750
-8,250
| -55% | -$164K |
|
1535
Ralph Lauren
RL
$20.1B
| $135K | ﹤0.01% |
772
+697
| +929% | +$120K |
|
|
RNAM
1536
DELISTED
Avidity Biosciences
RNAM
| $133K | ﹤0.01% |
3,263
-82
| -2% | -$2.35K |
|
1537
Commercial Vehicle Group
CVGI
$124M
| $132K | ﹤0.01% |
26,911
| – | – |
|
1538
Greif
GEF
$4.69B
| $132K | ﹤0.01% |
2,291
-540
| -19% | -$34.1K |
|
1539
Rivian
RIVN
$21.6B
| $132K | ﹤0.01% |
9,800
-547
| -5% | -$5.72K |
|
1540
Enact Holdings
ACT
$6.67B
| $130K | ﹤0.01% |
4,231
-35,251
| -89% | -$1.07M |
|
1541
Alto Neuroscience
ANRO
$1.18B
| $128K | ﹤0.01% |
12,000
+3,000
| +33% | +$39K |
|
1542
Descartes Systems
DSGX
$6.77B
| $126K | ﹤0.01% |
1,298
| – | – |
|
1543
Norfolk Southern
NSC
$71.4B
| $125K | ﹤0.01% |
583
-110
| -16% | -$25.5K |
|
1544
City Holding Co
CHCO
$2.01B
| $120K | ﹤0.01% |
1,134
| – | – |
|
1545
Quaker Houghton
KWR
$2.65B
| $120K | ﹤0.01% |
709
| – | – |
|
1546
Kyverna Therapeutics
KYTX
$428M
| $120K | ﹤0.01% |
+16,000
| New | +$244K |
|
|
SGMO
1547
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $120K | ﹤0.01% |
335,119
| – | – |
|
1548
MarketAxess Holdings
MKTX
$5.75B
| $118K | ﹤0.01% |
589
-5,370
| -90% | -$1.11M |
|
|
FLG
1549
Flagstar Bank National Association
FLG
$5.21B
| $117K | ﹤0.01% |
12,139
-1,622
| -12% | -$15.7K |
|
|
EXAI
1550
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $115K | ﹤0.01% |
+22,500
| New | +$111K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.